摘要
目的探讨安非他酮与喹硫平治疗双相情感障碍抑郁发作的临床疗效及安全性。方法将双相情感障碍抑郁发作患者68例随机分为安非他酮组和喹硫平组,每组34例,分别口服安非他酮与喹硫平治疗。采用汉密顿抑郁量表(HAMD)评定其临床疗效,用生活质量问卷(GQOLI)评定生活质量,应用副反应量表(TESS)评定不良反应。结果治疗后,两组HAMD评分均降低(P<0.05);治疗第1、2、4、6、8周,喹硫平组较安非他酮组降低,差异有统计学意义(P<0.05);喹硫平组显效率高于安非他酮组(P<0.05)。治疗8周后,喹硫平组躯体功能、心理功能、社会功能及GQOLI总分提高(P<0.05)。喹硫平组不良反应发生率、TESS评分低于安非他酮组(P<0.05),差异有统计学意义(P<0.05)。结论喹硫平治疗双相情感障碍抑郁发作疗效显著,患者依从性好,安全性高,可明显提高患者的生活质量,效果优于安非他酮。
Objective To investigate the clinical efficacy and safety of bupropion and quetiapine on depressive episodes of bipolar disorder. Methods 68 patients with depressive episodes of bipolar disorder were randomly divided into bupropion group and quetiapine group,34 cases in each group,patients received bupropion and quetiapine oral treatment respectively. The Hamilton depression rating scale（ HAM D）,generic quality of life inventory（ GQOLI） and treatment emergent symptom scale（ TESS） were used to assess the clinical efficacy,quality of life and adverse reactions. Results After treatment,HAM D score of the two groups decreased significantly（ P〈0. 05）,and the scores of patients in quetiapine group were low er than those of bupropion group at the 1st,2nd,4th,6th,8th week（ P〈0. 05）,the effective rate of quetiapine group was higher than that of bupropion group（ P〈0. 05）. After 8 weeks of treatment,the physical function,psychological function,social function and total score in GQOLI significantly increased（ P〈0. 05）. The rate of adverse drug reaction and TESS scores of quetiapine group were significantly low er than those of bupropion group（ P〈0. 05）. Conclusion The efficacy of quetiapine on depressive episodes of bipolar disorder is significant,with good compliance and high safety,it can significantly improve the quality of life,and the effect is better than bupropion.
出处
《实用药物与临床》
CAS
2015年第4期478-481,共4页
Practical Pharmacy and Clinical Remedies
